Literature DB >> 20413800

Dissolving oral clonazepam wafers in the acute treatment of prolonged seizures.

Matthew M Troester1, Eric V Hastriter, Yu-Tze Ng.   

Abstract

Klonopin (clonazepam; Genentech Inc, South San Francisco, California) oral wafers are benzodiazepines with anticonvulsive and anxiolytic properties. Our institution has been prescribing clonazepam wafers for acute treatment of prolonged seizures for years. Patients' size determined dosing at 0.25, 0.5, 1, or 2 mg wafers. We proceeded to obtain evidence for efficacy. Hospital Institutional Review Board approval was obtained for anonymous patient survey. All children who had been prescribed clonazepam wafers over a 6-year period at our institution were mailed detailed questionnaires. Three hundred eighty-one questionnaires were mailed with 88 replies but only 56 with meaningful data. Average age was 12.1 years. There were 31 males. Efficacy was defined as stopping seizure within 10 minutes, >50% of the time. Thirty-eight of the 56 (68%) patients met this criterion. From these 38 patients, 19 (50%) had seizures stop within 1 minute. Overall results were comparable to Diastat (rectal diazepam; Valeant Pharmaceuticals International, Aliso Viejo, California). Clonazepam wafers are an effective acute therapy for prolonged seizures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413800     DOI: 10.1177/0883073810368312

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  7 in total

Review 1.  Medication Use in Schools: Current Trends, Challenges, and Best Practices.

Authors:  Susan M Butler; Elizabeth A Boucher; Jennifer Tobison; Hanna Phan
Journal:  J Pediatr Pharmacol Ther       Date:  2020 Jan-Feb

Review 2.  Rescue therapies for seizures.

Authors:  Valeriya S Poukas; John R Pollard; Christopher Todd Anderson
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

3.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

4.  Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis.

Authors:  Moira Cruickshank; Mari Imamura; Corinne Booth; Lorna Aucott; Carl Counsell; Paul Manson; Graham Scotland; Miriam Brazzelli
Journal:  Health Technol Assess       Date:  2022-03       Impact factor: 4.106

Review 5.  A mini-review on drug delivery through wafer technology: Formulation and manufacturing of buccal and oral lyophilizates.

Authors:  Juliana Souza Ribeiro Costa; Karen de Oliveira Cruvinel; Laura Oliveira-Nascimento
Journal:  J Adv Res       Date:  2019-05-03       Impact factor: 10.479

Review 6.  Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability.

Authors:  Adam Strzelczyk; Laurent M Willems; Ricardo Kienitz; Lara Kay; Isabelle Beuchat; Sarah Gelhard; Sophie von Brauchitsch; Catrin Mann; Alexandra Lucaciu; Jan-Hendrik Schäfer; Kai Siebenbrodt; Johann-Philipp Zöllner; Susanne Schubert-Bast; Felix Rosenow
Journal:  CNS Drugs       Date:  2022-08-16       Impact factor: 6.497

Review 7.  Rescue therapies for seizure emergencies: current and future landscape.

Authors:  Debopam Samanta
Journal:  Neurol Sci       Date:  2021-07-16       Impact factor: 3.830

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.